Add BrightSurf on Google Email

Frequent COVID-19 testing key to efficient, early detection, study finds

A new study found that frequent COVID-19 testing, especially using polymerase chain reaction tests paired with rapid results reporting, can achieve 98% sensitivity in detecting infection. This approach can be particularly effective in places where vaccination is not yet widespread or when variants are on the rise.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalThe Journal of Infectious Diseases·DateJun 30, 2021

COVID-19 PCR tests can be freeze dried

Researchers at Northwestern University have discovered a method to make commercially available PCR tests shelf-stable for up to 30 days by freeze-drying the reagents with a standard preservative. This breakthrough could enable widespread COVID-19 testing in low-resource settings and reduce logistical challenges.

SourceNorthwestern University·JournalBiotechnology Journal·DateJun 11, 2021

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

The CASTLE study investigated the role of imaging-guided percutaneous cardiac intervention (PCI) in clinical outcomes difference between ultra-thin strut biodegradable polymer sirolimus-eluting stent (Orsiro) and durable polymer everolimus-eluting stents (Xience). The results show no significant differences in target lesion failure rat...

SourcePCR·DateMay 18, 2021

One-year results from the FUTURE-II trial

A randomized trial comparing a new, thin-strut bioresorbable scaffold with a metallic stent showed non-inferiority of the bioresorbable scaffold in terms of late lumen loss and covered struts. The trial's results may revitalize the concept of bioresorbable scaffolds.

SourcePCR·DateMay 18, 2021

The Lancet Respiratory Medicine: Rapid bedside testing is faster than standard centralised PCR testing for COVID-19, and may improve infection control in hospital

A study published in The Lancet Respiratory Medicine found that rapid bedside testing for COVID-19 can reduce time to results by up to 80 hours and improve infection control. The test, known as QIAstat-Dx POCT, allows patients to be quickly isolated and treatment to be started immediately.

SourceThe Lancet·JournalThe Lancet Respiratory Medicine·DateOct 8, 2020

Study demonstrates SARS-CoV-2 emergence was associated with a large drop in the circulation of other respiratory viruses during the first wave

A study found that SARS-CoV-2 emergence was associated with a significant decrease in the circulation of other common respiratory viruses. Patients with COVID-19 had worse clinical outcomes and were more likely to develop pneumonia compared to those with co-infections.

Universal virus detection platform to expedite viral diagnosis?

Researchers at KAIST developed a universal virus detection platform using reactive polymer-grafted double-stranded RNAs, which can detect viruses without prior knowledge of their genomic sequences. This platform provides enhanced sensitivity and can be used to quickly differentiate infected populations from non-infected ones.

Genetic barcodes can ensure authentic DNA fingerprints

Researchers propose genetic barcodes to guarantee DNA samples' authenticity before reaching the lab, mitigating cyberbiosecurity threats. The system introduces non-harmful material into samples as they're collected, which acts as a password ensuring their genuineness upon processing.

SourceDuke University·JournalIEEE Transactions on Information Forensics and Security·DateMay 21, 2020

Interventions with paclitaxel drug-coated balloons

The American Heart Association statement addresses the controversy surrounding paclitaxel-eluting stents and drug-coated balloons in peripheral interventions. Despite a 2018 meta-analysis suggesting increased mortality with paclitaxel exposure, individual sponsor-driven analyses have failed to replicate these findings.

SourcePCR·DateMay 21, 2019

Hepatitis C: A novel point-of-care assay

A novel point-of-care Hepatitis C assay has been developed to diagnose chronic cases in asymptomatic patients, particularly in low- and middle-income countries. The assay detects HCV RNA reliably, faster than existing methods, and can be used at the point of care, reducing the need for centralized laboratories.

SourceInstitut Pasteur·JournalGut·DateApr 10, 2018